IL144371A0 - Her-2/neu fusion proteins - Google Patents
Her-2/neu fusion proteinsInfo
- Publication number
- IL144371A0 IL144371A0 IL14437100A IL14437100A IL144371A0 IL 144371 A0 IL144371 A0 IL 144371A0 IL 14437100 A IL14437100 A IL 14437100A IL 14437100 A IL14437100 A IL 14437100A IL 144371 A0 IL144371 A0 IL 144371A0
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- neu
- neu fusion
- nucleic acid
- acid molecules
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11797699P | 1999-01-29 | 1999-01-29 | |
| PCT/US2000/002164 WO2000044899A1 (en) | 1999-01-29 | 2000-01-28 | Her-2/neu fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144371A0 true IL144371A0 (en) | 2002-05-23 |
Family
ID=22375831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14437100A IL144371A0 (en) | 1999-01-29 | 2000-01-28 | Her-2/neu fusion proteins |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1147190B1 (ja) |
| JP (1) | JP5164300B2 (ja) |
| KR (1) | KR100766653B1 (ja) |
| CN (1) | CN1201004C (ja) |
| AT (1) | ATE474048T1 (ja) |
| AU (1) | AU780109B2 (ja) |
| BR (1) | BR0007840A (ja) |
| CA (1) | CA2361009C (ja) |
| CZ (1) | CZ20012587A3 (ja) |
| DE (1) | DE60044665D1 (ja) |
| ES (1) | ES2348708T3 (ja) |
| HK (1) | HK1044798A1 (ja) |
| HU (1) | HUP0105303A2 (ja) |
| IL (1) | IL144371A0 (ja) |
| MX (1) | MXPA01007721A (ja) |
| NO (1) | NO20013701L (ja) |
| NZ (1) | NZ513062A (ja) |
| TR (1) | TR200102191T2 (ja) |
| WO (1) | WO2000044899A1 (ja) |
| ZA (1) | ZA200106179B (ja) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
| JP2003510334A (ja) | 1999-09-30 | 2003-03-18 | コリクサ コーポレイション | 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法 |
| US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| AU2744201A (en) * | 1999-12-29 | 2001-07-09 | Corixa Corporation | Murine neu sequences and methods of use therefor |
| DE60144516D1 (de) * | 2000-03-30 | 2011-06-09 | Dendreon Corp | Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie |
| US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
| JP2004522412A (ja) * | 2000-08-14 | 2004-07-29 | コリクサ コーポレイション | Ｈｅｒ−２／ｎｅｕ−関連悪性腫瘍の治療および診断のための組成物および方法 |
| CA2425358C (en) * | 2000-10-18 | 2012-08-21 | Glaxosmithkline Biologicals S.A. | A vaccine composition comprising qs21, mpl, a cpg oligonucleotide and a cancer antigen |
| ES2377077T3 (es) | 2000-10-18 | 2012-03-22 | Glaxosmithkline Biologicals S.A. | Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| NZ530315A (en) | 2001-07-10 | 2007-01-26 | Corixa Corp | Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| EP1590437A4 (en) | 2003-01-24 | 2008-06-18 | Agensys Inc | NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B |
| JP2007524654A (ja) * | 2003-06-06 | 2007-08-30 | エイジェニックス インコーポレイテッド | 癌ワクチン中のアジュバントとしてのラクトフェリン |
| DK1641819T3 (da) * | 2003-06-25 | 2009-08-03 | Bn Immunotherapeutics Inc | Oprensning af HER-2-varianter |
| KR20060033870A (ko) | 2003-06-25 | 2006-04-20 | 파멕사 에이/에스 | Ｈｅｒ-2 변이체의 정제 |
| EP1649020B1 (en) * | 2003-07-21 | 2017-01-11 | MSD Italia S.r.l. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| ITMI20041965A1 (it) * | 2004-10-15 | 2005-01-15 | Augusto Amici | "dna codificante forme tronche e chimeriche della proteina p185neu e suoi usi terapeutici" |
| GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP2032719A2 (en) | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| EP2148697B1 (en) | 2007-05-24 | 2012-10-03 | GlaxoSmithKline Biologicals S.A. | Lyophilised cpg containing wt-1 composition |
| AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
| GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
| EP2579897A1 (en) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
| KR101877598B1 (ko) | 2011-10-14 | 2018-07-11 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| PT2906296T (pt) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR101986404B1 (ko) | 2012-10-12 | 2019-06-07 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| SI2906251T1 (en) | 2012-10-12 | 2018-01-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| WO2014057120A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| NZ710745A (en) | 2013-03-13 | 2019-03-29 | Genentech Inc | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| US9649390B2 (en) | 2013-03-13 | 2017-05-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015023355A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| JP6425327B2 (ja) * | 2013-12-12 | 2018-11-21 | 国立大学法人東京農工大学 | タンパク質−磁性粒子複合体及びその製造方法 |
| JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
| BR112016013258A2 (pt) | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
| CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| CA2969689A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| JP7093767B2 (ja) | 2016-08-11 | 2022-06-30 | ジェネンテック， インコーポレイテッド | ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート |
| CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CA3047683C (en) | 2017-02-08 | 2020-03-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| LT3612537T (lt) | 2017-04-18 | 2022-10-10 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
| BR112019021880A2 (pt) | 2017-04-20 | 2020-06-02 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo anti-axl-droga |
| US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| LT3668874T (lt) | 2017-08-18 | 2022-03-25 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
| RU2020113749A (ru) | 2017-09-20 | 2021-10-20 | пиЭйч ФАРМА Ко., ЛТД. | Аналоги таиланстатина |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| WO2022013189A1 (en) * | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Assays for fixed dose combinations |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| KR102584276B1 (ko) * | 2023-03-30 | 2023-10-10 | 주식회사 애스톤사이언스 | Her2 백신, 및 면역관문 억제제의 조합 요법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2106033T3 (es) * | 1989-05-19 | 1997-11-01 | Genentech Inc | Dominio extracelular de her2. |
| US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| JPH0914357A (ja) * | 1995-06-27 | 1997-01-14 | Honda Motor Co Ltd | 伝動ベルト用ブロック |
-
2000
- 2000-01-28 TR TR2001/02191T patent/TR200102191T2/xx unknown
- 2000-01-28 DE DE60044665T patent/DE60044665D1/de not_active Expired - Lifetime
- 2000-01-28 WO PCT/US2000/002164 patent/WO2000044899A1/en not_active Application Discontinuation
- 2000-01-28 KR KR1020017009563A patent/KR100766653B1/ko not_active IP Right Cessation
- 2000-01-28 CN CNB008057524A patent/CN1201004C/zh not_active Expired - Fee Related
- 2000-01-28 ES ES00905800T patent/ES2348708T3/es not_active Expired - Lifetime
- 2000-01-28 CZ CZ20012587A patent/CZ20012587A3/cs unknown
- 2000-01-28 CA CA2361009A patent/CA2361009C/en not_active Expired - Fee Related
- 2000-01-28 MX MXPA01007721A patent/MXPA01007721A/es not_active Application Discontinuation
- 2000-01-28 AT AT00905800T patent/ATE474048T1/de not_active IP Right Cessation
- 2000-01-28 AU AU27426/00A patent/AU780109B2/en not_active Ceased
- 2000-01-28 NZ NZ513062A patent/NZ513062A/en unknown
- 2000-01-28 EP EP00905800A patent/EP1147190B1/en not_active Expired - Lifetime
- 2000-01-28 JP JP2000596141A patent/JP5164300B2/ja not_active Expired - Fee Related
- 2000-01-28 BR BR0007840-9A patent/BR0007840A/pt not_active IP Right Cessation
- 2000-01-28 IL IL14437100A patent/IL144371A0/xx unknown
- 2000-01-28 HU HU0105303A patent/HUP0105303A2/hu unknown
-
2001
- 2001-07-26 ZA ZA200106179A patent/ZA200106179B/en unknown
- 2001-07-27 NO NO20013701A patent/NO20013701L/no unknown
-
2002
- 2002-08-26 HK HK02106267A patent/HK1044798A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100766653B1 (ko) | 2007-10-15 |
| NO20013701D0 (no) | 2001-07-27 |
| TR200102191T2 (tr) | 2001-12-21 |
| KR20010101865A (ko) | 2001-11-15 |
| MXPA01007721A (es) | 2003-07-14 |
| CA2361009A1 (en) | 2000-08-03 |
| CN1345374A (zh) | 2002-04-17 |
| EP1147190A1 (en) | 2001-10-24 |
| JP2002535004A (ja) | 2002-10-22 |
| JP5164300B2 (ja) | 2013-03-21 |
| ZA200106179B (en) | 2002-12-24 |
| BR0007840A (pt) | 2002-01-22 |
| CZ20012587A3 (cs) | 2002-05-15 |
| ATE474048T1 (de) | 2010-07-15 |
| WO2000044899A1 (en) | 2000-08-03 |
| HK1044798A1 (en) | 2002-11-01 |
| DE60044665D1 (de) | 2010-08-26 |
| CA2361009C (en) | 2012-10-23 |
| NO20013701L (no) | 2001-09-28 |
| AU2742600A (en) | 2000-08-18 |
| AU780109B2 (en) | 2005-03-03 |
| NZ513062A (en) | 2003-10-31 |
| HUP0105303A2 (en) | 2002-05-29 |
| CN1201004C (zh) | 2005-05-11 |
| EP1147190B1 (en) | 2010-07-14 |
| ES2348708T3 (es) | 2010-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL144371A0 (en) | Her-2/neu fusion proteins | |
| WO2002012341A3 (en) | Her-2/neu fusion proteins | |
| HUP0302532A2 (hu) | Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások | |
| DE69634912D1 (de) | Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren | |
| TW428026B (en) | Bifunctional protein, preparation and use | |
| FI932678A0 (fi) | Pao alfavirus baserande DNA expressionssystem | |
| SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
| BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
| WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
| WO1998037093A3 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| WO2004030636A3 (en) | Human papillomavirus polypeptides and immunogenic compositions | |
| IL145731A0 (en) | A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same | |
| IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
| DE69924826D1 (de) | Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie | |
| ATE228016T1 (de) | Lebendvakzine zur behandlung von tumorerkrankungen | |
| WO2001040313A3 (en) | Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof | |
| IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
| HUP0302566A2 (hu) | Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására | |
| WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
| DE60131975D1 (de) | Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten | |
| AU2003234342A8 (en) | Ablated slam-dependent entry | |
| WO2003016343A3 (en) | USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS | |
| WO2001055391A3 (en) | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer | |
| DE69733320D1 (de) | Differenzierungsfaktor der hypophyse und methoden zu seiner verwendung. |